Tim Sprenger

Tim Sprenger

Auto-generated profile, based on publicly available information

Tim Sprenger

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2020 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
KRKyeong Hwa Ryu
Kyeong Hwa Ryu
HBHye Jin Baek
Hye Jin Baek
SSStefan Skare
Stefan Skare
JMJ.I. Moon
J.I. Moon
BCB.H. Choi
B.H. Choi
TST. Sprenger
T. Sprenger
BACKGROUND AND PURPOSE: The long scan time of MR imaging is a major drawback limiting its clinical use in neuroimaging; therefore, we aimed to investigate the clinical feasibility of a 1-minute full-brain MR imaging using a multicontrast EPI sequence on a different MR imaging scanner than the ones previously reported. MATERIALS AND METHODS: We retrospectively reviewed the records of 146 patients who underwent a multicontrast EPI sequence, including T1-FLAIR, T2-FLAIR, T2WI, DWI, and T2*WI sequences. Two attending neuroradiologists assessed the image quality of each sequence to compare the multicontrast EPI sequence with routine MR imaging protocols. We used the Wilcoxon signed rank test and McNemar test to compare the 2 MR imaging protocols. RESULTS: The multicontrast EPI sequence generally showed sufficient image quality of >2 points using a 4-point assessment scale. Regarding image quality and susceptibility artifacts, there was no significant difference between the multicontrast EPI sequence DWI and routine DWI (P > .05), attesting to noninferiority of the multicontrast EPI, whereas there were significant differences in the other 4 sequences between the 2 MR imaging protocols. CONCLUSIONS: The multicontrast EPI sequence showed sufficient image quality for clinical use with a shorter scan time; however, it was limited by inferior image quality and frequent susceptibility artifacts compared with routine brain MR imaging. Therefore, the multicontrast EPI sequence cannot completely replace the routine MR imaging protocol at present; however, it may be a feasible option in specific clinical situations such as screening, time-critical diseases or for use with patients prone to motion.

14 December 2021 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
TSTim Sprenger
Tim Sprenger
AKAnnika Kits
Annika Kits
ONOla Norbeck
Ola Norbeck
ANAdam van Niekerk
Adam van Niekerk
JBJohan Berglund
Johan Berglund
SSStefan Skare
Stefan Skare
Purpose: Implement a fast, motion‐robust pulse sequence that acquires T1‐weighted, T2‐weighted, T2*‐weighted, T2 fluid‐attenuated inversion recovery, and DWI data in one run with only one prescription and one prescan.Methods: A software framework was developed that configures and runs several sequences in one main sequence. Based on that framework, the NeuroMix sequence was implemented, containing motion robust single‐shot sequences using EPI and fast spin echo (FSE) readouts (without EPI distortions). Optional multi‐shot sequences that provide better contrast, higher resolution, or isotropic resolution could also be run within the NeuroMix sequence. An optimized acquisition order was implemented that minimizes times where no data is acquired.Results: NeuroMix is customizable and takes between 1:20 and 4 min for a full brain scan. A comparison with the predecessor EPIMix revealed significant improvements for T2‐weighted and T2 fluid‐attenuated inversion recovery, while taking only 8 s longer for a similar configuration. The optional contrasts were less motion robust but offered a significant increase in quality, detail, and contrast. Initial clinical scans on 1 pediatric and 1 adult patient showed encouraging image quality.Conclusion: The single‐shot FSE readouts for T2‐weighted and T2 fluid‐attenuated inversion recovery and the optional multishot FSE and 3D‐EPI contrasts significantly increased diagnostic value compared with EPIMix, allowing NeuroMix to be considered as a standalone brain MRI application.

11 March 2024 in Neuroradiology
Verified
Journal Article
Open access
PDF file
AKAnnika Kits
Annika Kits
JAJonathan Al-Saadi
Jonathan Al-Saadi
FLFrancesca De Luca
Francesca De Luca
FJFredrik Janzon
Fredrik Janzon
MMMichael V Mazya
Michael V Mazya
ADAnna Falk Delgado
Anna Falk Delgado
Purpose: To assess the performance of a 2.5-minute multi-contrast brain MRI sequence (NeuroMix) in diagnosing acute cerebral infarctions. Methods: Adult patients with a clinical suspicion of acute ischemic stroke were retrospectively included. Brain MRI at 3 T included NeuroMix and routine clinical MRI (cMRI) sequences, with DWI/ADC, T2-FLAIR, T2-weighted, T2*, SWI-EPI, and T1-weighted contrasts. Three radiologists (R1–3) independently assessed NeuroMix and cMRI for the presence of acute infarcts (DWI ↑, ADC = or ↓) and infarct-associated abnormalities on other image contrasts. Sensitivity, specificity, and the area under the receiver operating characteristic curve (AUC) were calculated and compared using DeLong’s test. Inter- and intra-rater agreements were studied with kappa statistics. Relative DWI (rDWI) and T2-FLAIR (rT2-FLAIR) signal intensity for infarctions were semi-automatically rendered, and the correlation between methods was evaluated. Results: According to the reference standard, acute infarction was present in 34 out of 44 (77%) patients (63 ± 17 years, 31 men). Other infarct-associated signal abnormalities were reported in similar frequencies on NeuroMix and cMRI (p > .08). Sensitivity for infarction detection was 94%, 100%, and 94% evaluated by R1, R2, R3, for NeuroMix and 94%, 100%, and 100% for cMRI. Specificity was 100%, 90%, and 100% for NeuroMix and 100%, 100%, and 100% for cMRI. AUC for NeuroMix was .97, .95, and .97 and .97, 1, and 1 for cMRI (DeLong p = 1, .32, .15), respectively. Inter- and intra-rater agreement was κ = .88–1. The correlation between NeuroMix and cMRI was R = .73 for rDWI and R = .83 for rT2-FLAIR. Conclusion: Fast multi-contrast MRI NeuroMix has high diagnostic performance for detecting acute cerebral infarctions.

13 January 2022 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
KRKyeong Hwa Ryu
Kyeong Hwa Ryu
HBHye Jin Baek
Hye Jin Baek
SSStefan Skare
Stefan Skare
ECEun Cho
Eun Cho
In Chul NamIn Chul Nam
In Chul Nam
TST. Sprenger
T. Sprenger
BACKGROUND AND PURPOSE: Contrast-enhanced 3D T1WI is a preferred sequence for brain tumor imaging despite the long scan time. This study investigated the clinical feasibility of ultrafast contrast-enhanced T1WI by 3D echo-planar imaging compared with a standard contrast-enhanced 3D MPRAGE sequence for evaluating intracranial enhancing lesions in oncology patients. MATERIALS AND METHODS: Sixty-one patients in oncology underwent brain MR imaging including both contrast-enhanced T1WI, 3D-EPI and 3D MPRAGE, in a single examination session for evaluating intracranial tumors. Two neuroradiologists evaluated image quality, lesion conspicuity, diagnostic confidence, number and size of the lesions, and contrast-to-noise ratio measurements from the 2 different sequences. RESULTS: Ultrafast 3D-EPI T1WI did not reveal significant differences in diagnostic confidence, contrast-to-noise ratiolesion/parenchyma, and the number of enhancing lesions compared with MPRAGE (P > .05). However, ultrafast 3D-EPI T1WI revealed inferior image quality, inferior anatomic delineation and greater susceptibility artifacts with fewer motion artifacts than images obtained with MPRAGE. The mean contrast-to-noise ratioWM/GM and visual conspicuity of the lesion on ultrafast 3D-EPI T1WI were lower than those of MPRAGE (P < .001). CONCLUSIONS: Ultrafast 3D-EPI T1WI showed comparable diagnostic performance with sufficient image quality and a 7-fold reduction in scan time for evaluating intracranial enhancing lesions compared with standard MPRAGE, even though it was limited by an inferior image quality and frequent susceptibility artifacts. Therefore, we believe that ultrafast 3D-EPI T1WI may be a viable option in oncology patients prone to movement during imaging studies.

1 April 2016
Verified
Conference Paper
Closed access
VGVladimir Golkov
Vladimir Golkov
TSTim Sprenger
Tim Sprenger
JSJonathan Sperl
Jonathan Sperl
MMMarion Menzel
Marion Menzel
MCMichael Czisch
Michael Czisch
DCDaniel Cremers
Daniel Cremers
Many limitations of diffusion MRI are due to the instability of the model fitting procedure. Major shortcomings of the model-based approach are a partial information loss due to model simplicity, long scan time requirements due to fitting instability, and the lack of knowledge about how the parameters of a given model would respond to previously unseen microstructural changes, possibly failing to detect certain previously unseen pathologies. Here we show that diffusion MRI pathology detection is feasible without any models and without any prior knowledge of specific pathological changes whatsoever. Instead, raw q-space measurements are used directly without a model, only healthy population data is used for reference, and any deviations in a patient dataset from the healthy reference database are detected using novelty detection methods. This is done in each voxel independently, i.e. without spatial bias.